Mankind Pharma Ltd (MANKIND) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Mankind Pharma reported strong Q1 FY26 results, with revenue growth of 25% YoY, reaching 3,003 crore.
- Domestic revenue grew by 19% YoY, driven by volume recovery, chronic segment outperformance, and BSV consolidation.
- Market share increased to 4.9% by value and 6.2% by volume.
- OTC business revenue grew by 15% YoY, driven by strong performance of key consumer brands.
- The company announced an interim dividend of 1 per share.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.